WO2008036966A3 - Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders - Google Patents
Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders Download PDFInfo
- Publication number
- WO2008036966A3 WO2008036966A3 PCT/US2007/079284 US2007079284W WO2008036966A3 WO 2008036966 A3 WO2008036966 A3 WO 2008036966A3 US 2007079284 W US2007079284 W US 2007079284W WO 2008036966 A3 WO2008036966 A3 WO 2008036966A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inflammation
- obesity
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention provides a method of reducing inflammation in a living cell of a subject. This method increases the level of lipoic acid synthase within the living cell thereby causing the reduction of the inflammation. Various embodiments and variants are contemplated, some of which are set forth in claim format at the end of this document. The aspects, embodiments, and variants so exemplified in the claims format should not be understood as limiting the invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84650106P | 2006-09-22 | 2006-09-22 | |
US60/846,501 | 2006-09-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008036966A2 WO2008036966A2 (en) | 2008-03-27 |
WO2008036966A3 true WO2008036966A3 (en) | 2008-11-06 |
Family
ID=39201358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/079284 WO2008036966A2 (en) | 2006-09-22 | 2007-09-24 | Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008036966A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8524656B2 (en) | 2008-07-08 | 2013-09-03 | Jacques Galipeau | GM-CSF and truncated CCL2 conjugates and methods and uses thereof |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013116238A1 (en) * | 2012-01-30 | 2013-08-08 | Sanrx Pharmaceuticals, Inc. | Calcium folate (cafolate) and therapeutic methods based thereon |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040235123A1 (en) * | 2001-04-20 | 2004-11-25 | Liao Hans H | Production of alpha-lipoic acid |
WO2006088246A1 (en) * | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Agent for controlling function of gpr34 receptor |
-
2007
- 2007-09-24 WO PCT/US2007/079284 patent/WO2008036966A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040235123A1 (en) * | 2001-04-20 | 2004-11-25 | Liao Hans H | Production of alpha-lipoic acid |
WO2006088246A1 (en) * | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Agent for controlling function of gpr34 receptor |
Non-Patent Citations (4)
Title |
---|
ALDONYTE ET AL.: "Circulating monocytes from healthy individuals and COPD patients", RESPIRATORY RESEARCH, 2003, XP021000001 * |
DATABASE CAPLUS [online] ITO ET AL.: "Preparation of N-acyl-amino derivatives for controlling functions of GRP34 receptor as antagonists or inverse agonists", Database accession no. (145:293345) * |
JANG ET AL.: "Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smooth muscle cells with or without alpha lipoic acid", PROTEOMICS, vol. 4, 2004, pages 3383 - 3393 * |
MERVAALA ET AL.: "Lipoic acid supplementation prevents angiotensin II-induced renal injury", KIDNEY INTERNATIONAL, vol. 64, 2003, pages 501 - 508 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008036966A2 (en) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1219306A1 (en) | Methods and compositions for sleep disorders and other disorders | |
ZA201008398B (en) | An electrochemically active composition,methods of making,and uses thereof | |
HK1209628A1 (en) | Methods, compounds, compositions and vehicles for delivering 3-amino- 1-propanesulfonic acid 3--1- | |
IL202203A0 (en) | Synthetic bile acid composition, method, and preparation | |
GB0907315D0 (en) | Polymeric acid precursor compositions and methods | |
IL185977A0 (en) | Dendritic cell compositions and methods | |
PL2894165T3 (en) | Methods and compositions for treating complement-associated disorders | |
PL2009122T3 (en) | Copper-zinc alloy, method for its manufacture and use | |
WO2009111586A3 (en) | Autonomous in vitro evolution | |
WO2007101161A8 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
AU2007243282A8 (en) | Compositions and methods for the treatment of cardiovascular disease | |
WO2011079307A3 (en) | Methods and compositions for treating neurological disorders | |
GB2465814B (en) | Method,composition and device for the treatment of enzymes and saccharides disorders | |
EP2269981A4 (en) | Vinylsulfonic acid, polymer of the same, and method for producing the same | |
WO2009120700A3 (en) | Inhibition of dcps | |
EP2205771A4 (en) | Method, alloy and component | |
GB0719367D0 (en) | Transcription factor decoys, compositions and methods | |
IL198286A0 (en) | Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels | |
WO2008036966A3 (en) | Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders | |
WO2009008997A3 (en) | Treatment of neuropathic pain | |
WO2010037130A3 (en) | Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore | |
EP1973874A4 (en) | Low protonation constant hydroxy acids | |
WO2009088939A3 (en) | Compositions and methods for treating neurodegenerative diseases | |
WO2010023658A3 (en) | Compositions and methods for the treatment of glioblastoma | |
GB201111470D0 (en) | Method, composition and device for the treatment of enzymes and saccharides disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07843053 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07843053 Country of ref document: EP Kind code of ref document: A2 |